Cancer immunotherapy targeting Wilms' tumor gene WT1 product

被引:163
作者
Oka, Y
Udaka, K
Tsuboi, A
Elisseeva, OA
Ogawa, H
Aozasa, K
Kishimoto, T
Sugiyama, H
机构
[1] Osaka Univ, Sch Med, Dept Clin Lab Sci, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan
[4] Kyoto Univ, Dept Biophys, Sakyo Ku, Kyoto, Japan
[5] Osaka Univ, Osaka, Japan
关键词
D O I
10.4049/jimmunol.164.4.1873
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Wilms' tumor gene WT1 is expressed at high levels not only in acute myelocytic and lymphocytic leukemia and in chronic myelocytic leukemia but also in various types of solid tumors including lung cancers. To determine whether the WT1 protein can serve as a target Ag for tumor-specific immunity, three 9-mer WT1 peptides (Db126, Db221, and Db235), which contain H-2D(b)-binding anchor motifs and have a comparatively higher binding affinity for H-2D(b) molecules, were tested in mice (C57BL/6, H-2D(b)) for in vivo induction of CTLs directed against these WT1 peptides, Only one peptide, Db126, with the highest binding affinity for H-2Db molecules induced vigorous CTL responses. The CTLs specifically lysed not only Db126-pulsed target cells dependently upon Db126 concentrations but also WT1-expressing tumor cells in an H-2D(b)-restricted manner. The sensitizing activity to the Db126-specific CTLs was recovered from the cell extract of WT1-expressing tumor cells targeted by the CTLs in the same retention time as that needed for the synthetic Db126 peptide in RP-HPLC, indicating that the Db126-specific CTLs recognize the Db126 peptide to kill WT1-expressing target cells. Furthermore, mice immunized with the Db126 peptide rejected challenges by WT1-expressing tumor cells and survived for a long time with no signs of autoaggression by the CTLs, Thus, the WT1 protein was identified as a novel tumor Ag, Immunotherapy targeting the WT1 protein should find clinical application for various types of human cancers.
引用
收藏
页码:1873 / 1880
页数:8
相关论文
共 60 条
[1]  
BRIEGER J, 1994, LEUKEMIA, V8, P2138
[2]   T-CELL TOLERANCE BY CLONAL ANERGY IN TRANSGENIC MICE WITH NONLYMPHOID EXPRESSION OF MHC CLASS-II I-E [J].
BURKLY, LC ;
LO, D ;
KANAGAWA, O ;
BRINSTER, RL ;
FLAVELL, RA .
NATURE, 1989, 342 (6249) :564-566
[3]   ISOLATION AND CHARACTERIZATION OF A ZINC FINGER POLYPEPTIDE GENE AT THE HUMAN CHROMOSOME-11 WILMS TUMOR LOCUS [J].
CALL, KM ;
GLASER, T ;
ITO, CY ;
BUCKLER, AJ ;
PELLETIER, J ;
HABER, DA ;
ROSE, EA ;
KRAL, A ;
YEGER, H ;
LEWIS, WH ;
JONES, C ;
HOUSMAN, DE .
CELL, 1990, 60 (03) :509-520
[4]   The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis [J].
Chang, CS ;
Brossay, L ;
Kronenberg, M ;
Kane, KP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (03) :483-491
[5]  
CHEEVER MA, 1977, J IMMUNOL, V119, P714
[6]   Heteroclitic immunization induces tumor immunity [J].
Dyall, R ;
Bowne, WB ;
Weber, LW ;
LeMaoult, J ;
Szabo, P ;
Moroi, Y ;
Piskun, G ;
Lewis, JJ ;
Houghton, AN ;
Nikolic-Zugic, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1553-1561
[7]   IDENTIFICATION OF AN IMMUNODOMINANT PEPTIDE OF HER-2/NEU PROTOONCOGENE RECOGNIZED BY OVARIAN TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTE LINES [J].
FISK, B ;
BLEVINS, TL ;
WHARTON, JT ;
IOANNIDES, CG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (06) :2109-2117
[8]   HUMAN GENE MAGE-3 CODES FOR AN ANTIGEN RECOGNIZED ON A MELANOMA BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES [J].
GAUGLER, B ;
VANDENEYNDE, B ;
VANDERBRUGGEN, P ;
ROMERO, P ;
GAFORIO, JJ ;
DEPLAEN, E ;
LETHE, B ;
BRASSEUR, F ;
BOON, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :921-930
[9]   HOMOZYGOUS DELETION IN WILMS-TUMORS OF A ZINC-FINGER GENE IDENTIFIED BY CHROMOSOME JUMPING [J].
GESSLER, M ;
POUSTKA, A ;
CAVENEE, W ;
NEVE, RL ;
ORKIN, SH ;
BRUNS, GAP .
NATURE, 1990, 343 (6260) :774-778
[10]  
Gjertsen MK, 1997, INT J CANCER, V72, P784, DOI 10.1002/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.3.CO